Suppression of glucose uptake by TMEM16A also generates secondary effects by enhancing gluconeogenesis and glucose metabolic disorder, thereby exacerbating insulin resistance, lipogenic events, inflammatory responses, and other NAFLD‐related events (Figure 7E). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.